Developer docs
API playgroundTry for free, no card

Search company profiles

Zivo Bioscience

Full company profile

uuid0004gkj

Namestring
Zivo Bioscience
Legal namestring
ZIVO Bioscience, Inc.
Company typeenum
Public
Founded yearint
1983
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersTroy, United States
HQ citystring
Troy
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
algal biomass ingredients, animal feed additives, bioactive compounds, functional food ingredients, nutritional supplements
Industry4 codes
PRIMARYAFADALAO
Non-Antibiotic Health & Performance Supplements (Immune, Gut Health, Stress/Heat Support)
SECONDARYAFAJAHAF
Algae & Seaweed Proteins (Microalgae/Spirulina, Macroalgae)
Agriculture & Food Production/Food Ingredients & Additives/Proteins & Protein Ingredients (Plant/Animal Proteins, Protein Isolates/Concentrates)
SECONDARYAFADAKAF
Phytogenics & Botanicals (Essential Oils, Plant Extracts)
Agriculture & Food Production/Animal Feed Manufacturing/Medicated & Functional Feed (Coccidiostats, Probiotics, Performance Additives)
SECONDARYHLAMAEAB
Livestock & Production Animal Therapeutics (Rx)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
NAICS code4 codes
  • Animal Food Manufacturing3111
  • Other Animal Food Manufacturing311119
  • Animal Food Manufacturing31111
  • Pesticide, Fertilizer, and Other Agricultural Chemical Manufacturing3253
SIC code3 codes
  • Medicinal Chemicals & Botanical Products2833
  • Agricultural Prod-Livestock & Animal Specialties200
  • Miscellaneous Food Preparations & Kindred Products2090
Product category
Algal Biomass and Bioactive Ingredients
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Algal Biomass Product Sales
TypeOthers
Description

Commercial revenue from sales of dried algal biomass product (Zivolife) as a human food or food ingredient through independent distributor ZWorldwide, Inc., with initial focus on North American green powder food market. Generated $119,025 in revenue for nine months ended September 30, 2025.

ir.zivobioscience.com
2Licensing Royalties
TypeLicensing Royalties
Description

Revenue from licensing bioactive ingredients or molecules derived from ZIVO's algae cultures to third parties. The company has Participation Agreements providing investors 44.78% revenue share of all license fees generated.

ir.zivobioscience.com
3Strategic Partnerships and Development Deals
TypeLicensing Royalties
Description

Future revenue anticipated from partnerships with global animal health companies for therapeutic products, including coccidiosis treatment for poultry and bovine mastitis treatment.

ir.zivobioscience.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Zivolife
Description

Brand name for ZIVO's dried algal biomass product sold as a human food or food ingredient, with initial focus on the North American green powder food market. Product contains Vitamin A, protein, iron, important fatty acids, non-starch polysaccharides and other micronutrients.

Core offering1 text field

ZIVO Bioscience develops and commercializes naturally derived nutritional compounds and bioactive molecules from proprietary freshwater algae strains (Kelbsormidium Flaccidum). Its primary commercial offering is the Zivolife brand of dried algal biomass sold as a functional food ingredient for humans and as a feed additive for animal health applications targeting poultry coccidiosis and bovine mastitis. The company also isolates and licenses proprietary bioactive compounds (including a TLR4 Inhibitor molecule) for therapeutic applications in human and animal health.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Zivo Bioscience is a U.S.-based R&D company operating in biotech and agtech sectors with a proprietary platform of optimized freshwater algae strains. The product portfolio centers on the Zivolife brand of algal biomass, which serves as the foundation for three distinct product forms: Algal Biomass (whole dried algae), Extract/Supernatant (processed bioactive extracts), and Bioactive Compounds (isolated therapeutic molecules). The company commercializes these through two primary segments: Animal Health Products (feed ingredients for poultry coccidiosis prevention and dairy cow mastitis management) and Human Nutrition Products (functional food ingredients for cholesterol management, immune support, and joint health). The platform is characterized as affordable, sustainable, adaptable, plant-based, non-GMO, and antibiotic-free.

Product and service5 records
1Zivolife Algal Biomass
CategoryFunctional Food Ingredient
Description

Branded dried algal biomass product derived from proprietary freshwater algae strains (Kelbsormidium Flaccidum), positioned as a functional food ingredient and nutritional supplement providing a plant-based, non-GMO, antibiotic-free, sustainable source of protein, fiber, Vitamin A, iron, important fatty acids, and non-starch polysaccharides with added health benefits for human consumption.

2Animal Health Products
CategoryAnimal Feed Additives and Health Products
Description

Algae-based feed ingredients and health products for dairy cows (promoting a healthy immune response to bovine mastitis) and poultry (boosting productivity and digestive efficiency). Includes a product candidate aimed at preventing coccidiosis in broiler chickens.

3Human Nutrition Products
CategoryHuman Functional Food Ingredients
Description

Functional food ingredients derived from algal biomass designed to promote healthy cholesterol balance, boost immune system function, aid muscle recovery, and support joint health in humans.

4Extract/Supernatant
CategoryBioactive Extracts
Description

Processed forms of the proprietary algal culture yielding bioactive extracts used in the development of health products and therapeutic applications.

5Bioactive Compounds (including TLR4 Inhibitor)
CategoryPharmaceutical Bioactive Compounds
Description

Isolated and characterized biologically active molecules derived from proprietary algal cultures, including the TLR4 Inhibitor molecule, available for licensing to third parties for use in human and animal health therapeutics targeting multiple disease situations through immune modulation.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-04-06
Description

ZIVO signed a manufacturing agreement with Cyanotech Corporation to grow, cultivate, and process its proprietary Zivolife algal biomass for commercial applications in animal health, human nutrition, and functional ingredients markets. Cyanotech operates a 96-acre production facility at NELHA on Hawaii's Big Island with over 40 years of microalgae cultivation expertise and cGMP operations with GRAS certification. The agreement provides scalable production capacity to meet anticipated global demand.

2ZWorldwide, Inc.
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Independent distributor engaged by ZIVO to sell Zivolife branded product in North American green powder food market. Distributor has begun selling product with algae grown in Peru.

ir.zivobioscience.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global animal nutrition and health company with algae-based feed ingredients (SP1) and a broad portfolio spanning poultry, dairy, and human nutrition. Highly comparable in animal health positioning and algae-derived ingredients.

TypeBroad incumbent
Description

One of the largest global animal feed and nutrition companies, with algae-based and functional feed additive offerings. Comparable in distribution scale, dairy and poultry customer base, and functional ingredient positioning.

TypeDirect peer
Description

Microalgae cultivation company operating the same 96-acre NELHA facility that produces ZIVO's biomass. Directly comparable in algae strain production, cGMP operations, and GRAS-certified ingredients for nutrition markets.

TypeDirect peer
Description

Animal health company with a strong coccidiostat portfolio (e.g., Salinomycin, Nicarbazin). Directly comparable to ZIVO's coccidiosis candidate in target disease, customer base (poultry producers), and regulatory pathway.

TypeBroad incumbent
Description

Global ingredient manufacturer focused on animal feed additives, pet food, and human nutrition. Overlaps with ZIVO's animal health (immune support, gut health) and functional food ingredients strategy.

TypeDirect peer
Description

Algae biotechnology company producing microalgae-based products for nutrition, wellness, and animal feed markets. Closely comparable to ZIVO in algal strain cultivation, biomass commercialization, and multi-segment go-to-market strategy.

TypeBroad incumbent
Description

Global leader in plant-based ingredients including algae-derived proteins for human nutrition and animal feed. Comparable in non-GMO, plant-based protein positioning for food, beverage, and nutraceutical markets.

TypeBroad incumbent
Description

Global leader in animal feed additives, premixes, and nutritional ingredients. Overlaps with ZIVO's non-antibiotic performance supplements (Verax product line) and human nutrition ingredients via DSM Nutritional Products.

TypeDirect peer
Description

Animal health and nutrition company with a portfolio of anticoccidial products for poultry and rumensin-related feed additives. Direct competitor in the coccidiosis prevention market that ZIVO is targeting.

TypeBroad incumbent
Description

Produces algae-based ingredients (AlgaPrime DHA) for animal nutrition and human food applications. Comparable in microalgae-derived functional ingredients targeting aquaculture, poultry, and human nutrition segments.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds15 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Zivo Bioscience

Algal Biomass and Bioactive Ingredientszivobioscience.com

Zivo Bioscience firmographics

Firmographics
Name
Zivo Bioscience
Legal name
ZIVO Bioscience, Inc.
Website
https://zivobioscience.com
Company type
Public
Founded year
1983
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Zivo Bioscience industry classification

Industry
Product category
Algal Biomass and Bioactive Ingredients
NAICS
Animal Food Manufacturing (3111), Other Animal Food Manufacturing (311119), Animal Food Manufacturing (31111), Pesticide, Fertilizer, and Other Agricultural Chemical Manufacturing (3253)
SIC
Medicinal Chemicals & Botanical Products (2833), Agricultural Prod-Livestock & Animal Specialties (200), Miscellaneous Food Preparations & Kindred Products (2090)
akta.pro industry
PRIMARYAFADALAO
Non-Antibiotic Health & Performance Supplements (Immune, Gut Health, Stress/Heat Support)
SECONDARYAFAJAHAF
Algae & Seaweed Proteins (Microalgae/Spirulina, Macroalgae)
Agriculture & Food Production/Food Ingredients & Additives/Proteins & Protein Ingredients (Plant/Animal Proteins, Protein Isolates/Concentrates)
SECONDARYAFADAKAF
Phytogenics & Botanicals (Essential Oils, Plant Extracts)
Agriculture & Food Production/Animal Feed Manufacturing/Medicated & Functional Feed (Coccidiostats, Probiotics, Performance Additives)
SECONDARYHLAMAEAB
Livestock & Production Animal Therapeutics (Rx)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics

Keywords

  • Algal biomass ingredients
  • Animal feed additives
  • Bioactive compounds
  • Functional food ingredients
  • Nutritional supplements

Where Zivo Bioscience is headquartered

Location

Headquarters

HQ city
Troy
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Zivo Bioscience business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales

Revenue model

  1. Algal Biomass Product Sales: Commercial revenue from sales of dried algal biomass product (Zivolife) as a human food or food ingredient through independent distributor ZWorldwide, Inc., with initial focus on North American green powder food market. Generated $119,025 in revenue for nine months ended September 30, 2025.
  2. Licensing Royalties: Revenue from licensing bioactive ingredients or molecules derived from ZIVO's algae cultures to third parties. The company has Participation Agreements providing investors 44.78% revenue share of all license fees generated.
  3. Strategic Partnerships and Development Deals: Future revenue anticipated from partnerships with global animal health companies for therapeutic products, including coccidiosis treatment for poultry and bovine mastitis treatment.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Zivo Bioscience product offering

Product offering

Core offering

ZIVO Bioscience develops and commercializes naturally derived nutritional compounds and bioactive molecules from proprietary freshwater algae strains (Kelbsormidium Flaccidum). Its primary commercial offering is the Zivolife brand of dried algal biomass sold as a functional food ingredient for humans and as a feed additive for animal health applications targeting poultry coccidiosis and bovine mastitis. The company also isolates and licenses proprietary bioactive compounds (including a TLR4 Inhibitor molecule) for therapeutic applications in human and animal health.

Product overview

Zivo Bioscience is a U.S.-based R&D company operating in biotech and agtech sectors with a proprietary platform of optimized freshwater algae strains. The product portfolio centers on the Zivolife brand of algal biomass, which serves as the foundation for three distinct product forms: Algal Biomass (whole dried algae), Extract/Supernatant (processed bioactive extracts), and Bioactive Compounds (isolated therapeutic molecules). The company commercializes these through two primary segments: Animal Health Products (feed ingredients for poultry coccidiosis prevention and dairy cow mastitis management) and Human Nutrition Products (functional food ingredients for cholesterol management, immune support, and joint health). The platform is characterized as affordable, sustainable, adaptable, plant-based, non-GMO, and antibiotic-free.

Differentiator

Problem solved

Functional benefit

Brands

  • Zivolife: Brand name for ZIVO's dried algal biomass product sold as a human food or food ingredient, with initial focus on the North American green powder food market. Product contains Vitamin A, protein, iron, important fatty acids, non-starch polysaccharides and other micronutrients.

Products and services

  • Zivolife Algal Biomass Branded dried algal biomass product derived from proprietary freshwater algae strains (Kelbsormidium Flaccidum), positioned as a functional food ingredient and nutritional supplement providing a plant-based, non-GMO, antibiotic-free, sustainable source of protein, fiber, Vitamin A, iron, important fatty acids, and non-starch polysaccharides with added health benefits for human consumption.
  • Animal Health Products Algae-based feed ingredients and health products for dairy cows (promoting a healthy immune response to bovine mastitis) and poultry (boosting productivity and digestive efficiency). Includes a product candidate aimed at preventing coccidiosis in broiler chickens.
  • Human Nutrition Products Functional food ingredients derived from algal biomass designed to promote healthy cholesterol balance, boost immune system function, aid muscle recovery, and support joint health in humans.
  • Extract/Supernatant Processed forms of the proprietary algal culture yielding bioactive extracts used in the development of health products and therapeutic applications.
  • Bioactive Compounds (including TLR4 Inhibitor) Isolated and characterized biologically active molecules derived from proprietary algal cultures, including the TLR4 Inhibitor molecule, available for licensing to third parties for use in human and animal health therapeutics targeting multiple disease situations through immune modulation.

Companies that use Zivo Bioscience

Customer profile

Segments3 records

Ideal customer profiles3 records

Zivo Bioscience technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Zivo Bioscience partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Cyanotech CorporationcoreTechnology or Integration · 6 April 2026ZIVO signed a manufacturing agreement with Cyanotech Corporation to grow, cultivate, and process its proprietary Zivolife algal biomass for commercial applications in animal health, human nutrition, and functional ingredients markets. Cyanotech operates a 96-acre production facility at NELHA on Hawaii's Big Island with over 40 years of microalgae cultivation expertise and cGMP operations with GRAS certification. The agreement provides scalable production capacity to meet anticipated global demand.
  • ZWorldwide, Inc.coreChannel Partner/ Reseller/ DistributorIndependent distributor engaged by ZIVO to sell Zivolife branded product in North American green powder food market. Distributor has begun selling product with algae grown in Peru.

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

Zivo Bioscience competitors and assessment

Company assessment

Broad incumbents

  • Alltech: Global animal nutrition and health company with algae-based feed ingredients (SP1) and a broad portfolio spanning poultry, dairy, and human nutrition. Highly comparable in animal health positioning and algae-derived ingredients.
  • Cargill Animal Nutrition: One of the largest global animal feed and nutrition companies, with algae-based and functional feed additive offerings. Comparable in distribution scale, dairy and poultry customer base, and functional ingredient positioning.
  • Kemin Industries: Global ingredient manufacturer focused on animal feed additives, pet food, and human nutrition. Overlaps with ZIVO's animal health (immune support, gut health) and functional food ingredients strategy.
  • Roquette: Global leader in plant-based ingredients including algae-derived proteins for human nutrition and animal feed. Comparable in non-GMO, plant-based protein positioning for food, beverage, and nutraceutical markets.
  • DSM-Firmenich (Animal Nutrition & Health): Global leader in animal feed additives, premixes, and nutritional ingredients. Overlaps with ZIVO's non-antibiotic performance supplements (Verax product line) and human nutrition ingredients via DSM Nutritional Products.
  • Corbion: Produces algae-based ingredients (AlgaPrime DHA) for animal nutrition and human food applications. Comparable in microalgae-derived functional ingredients targeting aquaculture, poultry, and human nutrition segments.

Direct peers

  • Cyanotech Corporation: Microalgae cultivation company operating the same 96-acre NELHA facility that produces ZIVO's biomass. Directly comparable in algae strain production, cGMP operations, and GRAS-certified ingredients for nutrition markets.
  • Phibro Animal Health: Animal health company with a strong coccidiostat portfolio (e.g., Salinomycin, Nicarbazin). Directly comparable to ZIVO's coccidiosis candidate in target disease, customer base (poultry producers), and regulatory pathway.
  • Heliae Development: Algae biotechnology company producing microalgae-based products for nutrition, wellness, and animal feed markets. Closely comparable to ZIVO in algal strain cultivation, biomass commercialization, and multi-segment go-to-market strategy.
  • Huvepharma: Animal health and nutrition company with a portfolio of anticoccidial products for poultry and rumensin-related feed additives. Direct competitor in the coccidiosis prevention market that ZIVO is targeting.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Zivo Bioscience social profiles

Digital presence

Zivo Bioscience compliance and trust

Trust signal

Compliance2 records

Zivo Bioscience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Zivo Bioscience leadership team

Management profile

Number of profiles

Profiles9 records

Zivo Bioscience funding detail

Funding detail

Funding overview

Funding rounds15 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Zivo Bioscience M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zivo Bioscience

What does Zivo Bioscience do?

ZIVO Bioscience develops and commercializes naturally derived nutritional compounds and bioactive molecules from proprietary freshwater algae strains (Kelbsormidium Flaccidum). Its primary commercial offering is the Zivolife brand of dried algal biomass sold as a functional food ingredient for humans and as a feed additive for animal health applications targeting poultry coccidiosis and bovine mastitis. The company also isolates and licenses proprietary bioactive compounds (including a TLR4 Inhibitor molecule) for therapeutic applications in human and animal health.

Is Zivo Bioscience a public or private company?

Zivo Bioscience is a public company. It is classified as public and is currently operating.

When was Zivo Bioscience founded?

Zivo Bioscience was founded in 1983. It employs 1 to 10 people.

Where is Zivo Bioscience based?

Zivo Bioscience is headquartered in Troy, United States, in the North America region.

How does Zivo Bioscience make money?

Three revenue lines are on record. Algal Biomass Product Sales are the primary driver. The others are licensing Royalties and strategic Partnerships and Development Deals.

Who are Zivo Bioscience's main competitors?

Broad incumbents on record are Alltech, Cargill Animal Nutrition, Kemin Industries, Roquette, DSM-Firmenich (Animal Nutrition & Health) and Corbion. Direct peers are Cyanotech Corporation, Phibro Animal Health, Heliae Development and Huvepharma.

Does Zivo Bioscience have an API?

No public API is recorded for Zivo Bioscience.

What industry is Zivo Bioscience in?

Zivo Bioscience's product category is Algal Biomass and Bioactive Ingredients. Its primary akta.pro industry code is AFADALAO, Non-Antibiotic Health & Performance Supplements (Immune, Gut Health, Stress/Heat Support), with a secondary code of AFAJAHAF, Algae & Seaweed Proteins (Microalgae/Spirulina, Macroalgae). Its NAICS code is 3111 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Ticker ReportZIVO Bioscience (NASDAQ:ZIVO) Share Price Crosses Below Two Hundred Day Moving Average – Here’s What HappenedZIVO Bioscience shares fell below their 200-day moving average on Thursday, trading as low as $3.33 against a 200-day average of $4.76. The clinical-stage biotech, focused on live biotherapeutics for gastrointestinal infections, has a market cap of $17.28 million and a pipeline including ZB-01 for C. difficile and ZB-02 for poultry Salmonella.Investing.comZivo Bioscience transitions stock to OTCID marketplace By Investing.comZivo Bioscience, Inc. transitioned its common stock to the OTCID marketplace on Monday, moving from its previous trading venue to a tier within OTC Markets for companies publishing baseline disclosures. The company, with a market capitalization of $15.21 million, has seen its stock decline 78% over the past year despite reporting 165% revenue growth over the last twelve months. The transition allows the company to maintain an efficient public market presence while streamlining reporting requirements, according to CEO John B. Payne.Stock TitanZivo Bioscience stock moves to OTCID marketplaceZivo Bioscience, Inc. announced the transition of its common stock to quotation on the OTCID marketplace, effective May 11, 2026. The OTCID tier is an OTC Markets segment for companies that publish baseline disclosure and maintain current information through OTC Markets' disclosure systems, offering streamlined reporting requirements and improved flexibility. CEO John B. Payne stated the move supports the company's commitment to transparency while allowing it to focus on advancing scientific and commercial objectives, with existing shareholders retaining their positions without any required action.Business Wire BlogZivo Bioscience, Inc. Announces Transition to OTCID MarketplaceZivo Bioscience announced it is transitioning its common stock to quotation on the OTCID marketplace, effective Monday, May 11, 2026. The company will continue to provide required corporate and financial information through its OTC Markets disclosure page. All existing shareholders will retain their positions through the transition.Investing.comMark E. Strome affiliate buys $200,000 in Zivo Bioscience stock By Investing.comAn affiliate of Mark E. Strome, a 10% owner of Zivo Bioscience, acquired 100,000 shares of the company's common stock for $200,000 on April 17, 2026, purchasing at $2.00 per share—significantly above the current trading price of $1.20. Following the transaction, the Reporting Persons indirectly hold 572,942 shares of Zivo Bioscience common stock. The stock has declined 43% over the past week and 93% over the past year, with the company carrying a market cap of $4.79 million and a "Weak" financial health score.DBusiness MagazineZIVO Bioscience in Troy Secures Commercial-scale Manufacturing AgreementZivo Bioscience Inc., a Troy-based biotech company, has signed a manufacturing agreement with Cyanotech Corp. in Hawaii to produce its proprietary algal biomass (Kelbsormidium Flaccidum) for the Zivolife product line serving animal health, human nutrition, and functional ingredients markets. The agreement gives ZIVO access to Cyanotech's 96-acre production facility at NELHA, over 40 years of microalgae cultivation expertise, and cGMP operations with GRAS certification. The company says this partnership is a critical step toward enabling initial commercial revenues and building a reliable supply chain to meet anticipated global market demand.AijournZIVO Bioscience Provides Special Letter to ShareholdersZIVO Bioscience, Inc. has announced its decision to deregister its securities with the Securities and Exchange Commission and cease public reporting, citing the disproportionate financial burden of maintaining a public listing. The company states this move will eliminate ongoing shareholder dilution from repeated financing rounds and expects to achieve positive cash flow for the first time through anticipated AgTech revenue and reduced operating costs. Major global animal health companies are advancing internal due diligence on ZIVO's non-antibiotic immune-modulating technology, and the University of Georgia plans to use their product in Avian Influenza studies funded by the Department of Agriculture.Business Wire BlogZIVO Bioscience Provides Special Letter to ShareholdersZIVO Bioscience's Board of Directors has decided to deregister the company's securities with the SEC and cease public reporting, citing the disproportionate costs of maintaining a public listing for a company with early-stage revenue. The company states that SEC compliance, legal, audit, and investor relations costs consume significant resources, and that repeated financing rounds to fund these expenses have caused ongoing shareholder dilution. Management expects the reduction in compliance overhead combined with anticipated revenue from its AgTech distribution partner to result in positive cash flow for the first time in the company's history.Stock TitanZIVO Bioscience to deregister, end SEC reportingZIVO Bioscience, Inc. has announced that its Board of Directors has decided to deregister the company's securities with the Securities and Exchange Commission and cease public reporting. The company cited the significant costs of maintaining its public listing—including SEC compliance, legal, financial reporting, and audit fees—as well as ongoing shareholder dilution from repeated financing rounds as the primary reasons for this decision. ZIVO expects that ceasing public reporting, combined with anticipated revenue from its AgTech product line through an established distribution partner, will result in positive cash flow for the first time in the company's history.